Triple-negative breast cancer (TNBC), an aggressive form of the disease that is more common in people under 40 who are Black or have a BRCA1 mutation, is more likely to return after treatment and has a worse prognosis than other breast cancers. Sylvia Adams, MD, director of the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center, talks to CBS New York about the addition of immunotherapy to the standard chemotherapy, an advance in treatment that was beneficial to Rene Williams, one of her patients.
“We actually had a very early, good, clinical response and were able to take her to surgery earlier,” says Dr. Adams, also a professor in the Department of Medicine at NYU Grossman School of Medicine. “And she had no residual cancer at time of surgery, which predicts an excellent outcome and cure.”
Watch more on CBS New York.